Form 4: Ocular Therapeutix CFO Receives Equity Grant

CFO Jason Shand Robins received a grant of 15,441 restricted stock units and 14,024 stock options from Ocular Therapeutix.

Summary

• Jason Shand Robins, Chief Financial Officer of Ocular Therapeutix, Inc., was granted 15,441 restricted stock units (RSUs) on June 10, 2026.
• The reporting person also received a stock option grant for 14,024 shares with an exercise price of $8.74.
• The RSUs vest over a three-year period, with one-third vesting annually.
• The stock options vest monthly over a four-year period, beginning one month after the grant date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding executive compensation, which is neutral in terms of immediate market impact.

Positives

• Equity-based compensation aligns the interests of the CFO with long-term shareholder value.
• Vesting schedules for both RSUs and options encourage long-term retention of key executive talent.

Negatives

• The issuance of new equity awards results in minor dilution to existing shareholders.

Risks

• Continued service requirements for vesting create dependency on the executive's ongoing employment.
• Stock option value is subject to market volatility and the future performance of the company's common stock.

Future Outlook

The equity grants are subject to continued service requirements, implying management's expectation of the executive's long-term commitment to the company's strategic goals.

Industry Context

StockSavvy.ai notes that equity grants to C-suite executives are standard corporate governance practices in the biotechnology sector to ensure leadership alignment with long-term R&D and commercialization milestones.

Comparison to Industry Standards

• The use of a mix of RSUs and stock options is consistent with standard executive compensation packages in the mid-cap biotech industry.
• Vesting periods of three to four years are aligned with industry benchmarks for executive retention.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of RSUs on the one-year anniversary of the grant date.
• Monthly vesting of stock options beginning one month after the grant date.

Key Dates

Keywords

Ocular Therapeutix, OCUL, Form 4, Insider Trading, Equity Compensation, CFO, Stock Options, Restricted Stock Units